NCT06685536Enrolling by invitation
A Long-term Follow-up Study in Participants Who Received CS-101
A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With Base-edited Autologous Hematopoietic Stem Cell (CS-101) Transplantation
Source: ClinicalTrials.gov · Last updated 10 Feb 2026
Brief summary (registry, in English)
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876),No investigational drug product will be administered in the study.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 5 (estimated)
- First submitted
- 7 Nov 2024
- Start date
- 18 Jan 2025
- Primary completion date
- Jul 2039
- Lead sponsor
- CorrectSequence Therapeutics Co., Ltd
- Diseases
- Thalassaemia
- NCT number
- NCT06685536
What you commit to
- Study type: Observational
- Planned participants: 5
- From 18 Jan 2025 to the primary completion date, Jul 2039
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- There are no exclusion criteria
Who the study is looking for
- Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form
- Participants must have received CS-101 infusion in last study
Age in the registry: 6 years to 35 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Guangxi Medical University Coordinator of this site? Confirm its status | Nanning | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.